Skip to content

Study · Non-randomized trial · n = 53 · 2014

5 results

Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.

Jayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Sridharan M, Mason AJ, Warwick J, Ashby D, Ghatei MA and 4 more

Show all authors

Bloom SR, Carby A, Trew GH, Dhillo WS

The Journal of clinical investigation18 Jul 2014Cited by 109 (Europe PMC)

PMID25036713 (opens in a new tab)PMCIDPMC4109525 (opens in a new tab)DOI10.1172/jci75730 (opens in a new tab)PepBankPUB-25036713
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women undergoing in vitro fertilization, egg maturation was observed after each tested dose of kisspeptin‑54.

    In plain wordsIn women having IVF, a single kisspeptin‑54 injection led to egg maturation at every dose tested.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableEgg maturation after kisspeptin-54
    Study

    n = 53

    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.6-12.8 nmol/kg · subcutaneous · single injectionAs given in this study (human).

    Source sentences

    Summary
    Egg maturation was observed in response to each tested dose of kisspeptin-54
    2 context sentences
    Summary · context
    Eggs were retrieved transvaginally 36 hours after kisspeptin injection, assessed for maturation (primary outcome), and fertilized by intracytoplasmic sperm injection with subsequent transfer of one or two embryos.
    Summary · context
    Following superovulation with recombinant follicle-stimulating hormone and administration of gonadotropin-releasing hormone antagonist to prevent premature ovulation, 53 women were administered a single subcutaneous injection of kisspeptin-54 (1.6 nmol/kg, n = 2; 3.2 nmol/kg, n = 3; 6.4 nmol/kg, n =…
  2. 02HumanNon-randomized trialEfficacy outcome

    In women undergoing in vitro fertilization, the mean number of mature eggs per patient generally increased in a dose-dependent manner.

    In plain wordsIn women having IVF, the number of mature eggs generally rose as the kisspeptin‑54 dose rose.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseMean number of mature eggs per patient
    Study

    n = 53

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.6-12.8 nmol/kg · subcutaneous · single injectionAs given in this study (human).

    Source sentences

    Summary
    the mean number of mature eggs per patient generally increased in a dose-dependent manner.
    1 context sentence
    Summary · context
    Following superovulation with recombinant follicle-stimulating hormone and administration of gonadotropin-releasing hormone antagonist to prevent premature ovulation, 53 women were administered a single subcutaneous injection of kisspeptin-54 (1.6 nmol/kg, n = 2; 3.2 nmol/kg, n = 3; 6.4 nmol/kg, n =…
  3. 03HumanNon-randomized trialEfficacy outcome

    Fertilization of eggs and transfer of embryos to the uterus occurred in 92% (49/53) of kisspeptin‑54-treated patients.

    In plain wordsIn women having IVF, 92% of those treated with kisspeptin‑54 had eggs fertilized and embryos transferred.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableFertilization and embryo transfer
    Study

    n = 53

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.6-12.8 nmol/kg · subcutaneous · single injectionAs given in this study (human).

    Measurements

    Fertilization and embryo transfer rate
    92%
    kisspeptin-54-treated patients

    Source sentences

    Summary
    Fertilization of eggs and transfer of embryos to the uterus occurred in 92% (49/53) of kisspeptin-54-treated patients.
    1 context sentence
    Summary · context
    Following superovulation with recombinant follicle-stimulating hormone and administration of gonadotropin-releasing hormone antagonist to prevent premature ovulation, 53 women were administered a single subcutaneous injection of kisspeptin-54 (1.6 nmol/kg, n = 2; 3.2 nmol/kg, n = 3; 6.4 nmol/kg, n =…
  4. 04HumanNon-randomized trialEfficacy outcome

    The biochemical pregnancy rate was 40% (21/53) in women treated with kisspeptin‑54 for egg maturation.

    In plain wordsIn women having IVF, 40% of those treated with kisspeptin‑54 had a biochemical pregnancy.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableBiochemical pregnancy rate
    Study

    n = 53

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.6-12.8 nmol/kg · subcutaneous · single injectionAs given in this study (human).

    Measurements

    Biochemical pregnancy rate
    40%
    kisspeptin-54-treated patients

    Source sentences

    Summary
    Biochemical and clinical pregnancy rates were 40% (21/53)
    1 context sentence
    Summary · context
    Following superovulation with recombinant follicle-stimulating hormone and administration of gonadotropin-releasing hormone antagonist to prevent premature ovulation, 53 women were administered a single subcutaneous injection of kisspeptin-54 (1.6 nmol/kg, n = 2; 3.2 nmol/kg, n = 3; 6.4 nmol/kg, n =…
  5. 05HumanNon-randomized trialEfficacy outcome

    The clinical pregnancy rate was 23% (12/53) in women treated with kisspeptin‑54 for egg maturation.

    In plain wordsIn women having IVF, 23% of those treated with kisspeptin‑54 had a clinical pregnancy.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableClinical pregnancy rate
    Study

    n = 53

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.6-12.8 nmol/kg · subcutaneous · single injectionAs given in this study (human).

    Measurements

    Clinical pregnancy rate
    23%
    kisspeptin-54-treated patients

    Source sentences

    Summary
    Biochemical and clinical pregnancy rates were 40% (21/53) and 23% (12/53), respectively.
    1 context sentence
    Summary · context
    Following superovulation with recombinant follicle-stimulating hormone and administration of gonadotropin-releasing hormone antagonist to prevent premature ovulation, 53 women were administered a single subcutaneous injection of kisspeptin-54 (1.6 nmol/kg, n = 2; 3.2 nmol/kg, n = 3; 6.4 nmol/kg, n =…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT01667406

The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment

Imperial College Londonn = 1751 Jun 2012 to 11 Oct 2016

Infertility

Trial pageClinicalTrials.govUpdated 8 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.